A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor

Pancreatic Ductal Adenocarcinoma (PDAC) is a disease with a great heterogeneity in the response to treatments. To improve the responsiveness to treatments there are two different approaches, the first one consist to develop new and more efficient drugs that intent to cure all patients and the second...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Gayet, Odile, Loncle, Celine, Duconseil, Pauline, Gilabert, Marine, Lopez, Maria Belen, Moutardier, Vincent, Turrini, Olivier, Calvo, Ezequiel, Ewald, Jacques, Giovannini, Marc, Gasmi, Mohamed, Bories, Erwan, Barthet, Marc, Ouaissi, Mehdi, Goncalves, Anthony, Poizat, Flora, Raoul, Jean Luc, Secq, Veronique, Garcia, Stephane, Viens, Patrice, Dusetti, Nelson, Iovanna, Juan
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2014
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359252/
https://ncbi.nlm.nih.gov/pubmed/25481873
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires